Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals

Table 6 Indications excluded from selected analyses^a on the basis of disproportionately low disease prevalence among females

Drug	Indication
Rilpivirine hydrochloride	Human immunodeficiency Virus
Abiraterone acetate	Prostate cancer
Avanafil	Erectile dysfunction
Enzalutamide	Prostate cancer
Crofelemer	Patients with diarrhea and HIV infection on antiretroviral therapy
Cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	Human immunodeficiency Virus
Radium Ra-223 dichloride	Prostate cancer
Dolutegravir sodium	Human immunodeficiency Virus

ISSN: 1745-6215